{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:22:53Z","timestamp":1790997773240,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visceral leishmaniasis (VL) in patients with human immunodeficiency virus (HIV) presents an increasingly important patient cohort in areas where both infections are endemic. Evidence for treatment is sparce, with no high-quality studies from the Indian subcontinent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a randomized, open-label, parallel-arm, phase 3 trial conducted within a single hospital in Patna, India. One hundred and fifty patients aged \u226518 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40\u00a0mg\/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30\u00a0mg\/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1.4\u00a0g oral miltefosine administered through 2 daily doses of 50\u00a0mg over 14 days. The primary outcome was intention-to-treat relapse-free survival at day 210, defined as absence of signs and symptoms of VL or, if symptomatic, negative parasitological investigations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 243 patients assessed for eligibility, 150 were recruited between 2 January 2017 and 5 April 2018, with no loss to follow-up. Relapse-free survival at day 210 was 85% (64\/75; 95% CI, 77\u2013100%) in the monotherapy arm, and 96%, (72\/75; 90\u2013100%) in the combination arm. Nineteen percent (28\/150) were infected with concurrent tuberculosis, divided equally between arms. Excluding those with concurrent tuberculosis, relapse-free survival at day 210 was 90% (55\/61; 82\u2013100%) in the monotherapy and 97% (59\/61; 91\u2013100%) in the combination therapy arm. Serious adverse events were uncommon and similar in each arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination therapy appears to be safe, well tolerated, and effective, and halves treatment duration of current recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>Clinical Trial Registry India (CTRI\/2015\/05\/005807; the protocol is available online at https:\/\/osf.io\/avz7r).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac127","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T15:13:26Z","timestamp":1644419606000},"page":"1423-1432","source":"Crossref","is-referenced-by-count":40,"title":["AmBisome Monotherapy and Combination AmBisome\u2013Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-8633","authenticated-orcid":false,"given":"Sakib","family":"Burza","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"},{"name":"London School of Hygiene and Tropical Medicine , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Mahajan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahwar","family":"Kazmi","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Alexander","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Lasry","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Harshana","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"de Lima Pereira","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Das","sequence":"additional","affiliation":[{"name":"Rajendra Memorial Research Institute of Medical Sciences , Patna , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Verma","sequence":"additional","affiliation":[{"name":"Rajendra Memorial Research Institute of Medical Sciences , Patna , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya Nand Ravi","family":"Das","sequence":"additional","affiliation":[{"name":"Rajendra Memorial Research Institute of Medical Sciences , Patna , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Shekhar","family":"Lal","sequence":"additional","affiliation":[{"name":"Rajendra Memorial Research Institute of Medical Sciences , Patna , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Rewari","sequence":"additional","affiliation":[{"name":"National Aids Control Organisation , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Goyal","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Rijal","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Gill","sequence":"additional","affiliation":[{"name":"National Vector Borne Disease Control Programme , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[{"name":"Rajendra Memorial Research Institute of Medical Sciences , Patna , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"2022101219181783400_CIT0001","volume-title":"Report of the Fifth Consultative Meeting on Leishmania\/HIV Coinfection AA","author":"WHO.","year":"2007"},{"key":"2022101219181783400_CIT0002","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence.","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"2022101219181783400_CIT0003","author":"National AIDS Control Organisation."},{"key":"2022101219181783400_CIT0004","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2012.00080","article-title":"T helper1\/T helper2 cells and resistance\/susceptibility to leishmania infection: is this paradigm still relevant?","volume":"3","author":"Alexander","year":"2012","journal-title":"Front Immunol"},{"key":"2022101219181783400_CIT0005","doi-asserted-by":"crossref","first-page":"e1002635","DOI":"10.1371\/journal.ppat.1002635","article-title":"Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection.","volume":"8","author":"Mock","year":"2012","journal-title":"PLoS Pathog"},{"key":"2022101219181783400_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e32835c2198","article-title":"Clinical aspects of visceral leishmaniasis in HIV infection.","volume":"26","author":"Jarvis","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2022101219181783400_CIT0007","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years.","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"2022101219181783400_CIT0008","doi-asserted-by":"crossref","first-page":"e2195","DOI":"10.1371\/journal.pntd.0002195","article-title":"Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.","volume":"7","author":"Cota","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022101219181783400_CIT0009","doi-asserted-by":"crossref","first-page":"e0006988","DOI":"10.1371\/journal.pntd.0006988","article-title":"A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.","volume":"13","author":"Diro","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2022101219181783400_CIT0010","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis.","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"2022101219181783400_CIT0011","article-title":"WHO control of the leishmaniasis","author":"World Health Organization.","year":"2010"},{"key":"2022101219181783400_CIT0012","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions.","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"2022101219181783400_CIT0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-3-11","article-title":"Adaptive design methods in clinical trials\u2014a review.","volume":"3","author":"Chow","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"2022101219181783400_CIT0014","doi-asserted-by":"crossref","first-page":"ofy059","DOI":"10.1093\/ofid\/ofy059","article-title":"Tuberculosis in visceral leishmaniasis-human immunodeficiency virus coinfection: an evidence gap in improving patient outcomes?","volume":"5","author":"Van Griensven","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2022101219181783400_CIT0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data.","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"key":"2022101219181783400_CIT0016","doi-asserted-by":"crossref","first-page":"e0227911","DOI":"10.1371\/journal.pone.0227911","article-title":"Quality of life perceptions amongst patients co-infected with visceral leishmaniasis and HIV: a qualitative study from Bihar, India.","volume":"15","author":"Nair","year":"2020","journal-title":"PLoS One"},{"key":"2022101219181783400_CIT0017","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2022101219181783400_CIT0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14787210.2019.1555471","article-title":"Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review.","volume":"17","author":"Sunyoto","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022101219181783400_CIT0019","first-page":"28","article-title":"Nosocomial infections in HIV-positive patients: an overview.","volume":"31","author":"Petrosillo","year":"2003","journal-title":"Infection"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac127\/43291764\/ciac127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1423\/46468729\/ciac127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1423\/46468729\/ciac127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T15:19:22Z","timestamp":1665587962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/8\/1423\/6527047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,11]]},"published-print":{"date-parts":[[2022,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac127","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,15]]},"published":{"date-parts":[[2022,2,11]]}}}